Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs,  announced the company has entered into a Research Agreement on 13^thAugust, 2024, for two molecules with undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. ("Chugai"). The full analysis confirms the RaniPill^®delivery demonstrated comparable bioavailability to the subcutaneous route of delivery for both molecules studied.

 "We are delighted to explore the opportunity of a collaboration with Chugai, a world-class industry leader with deep research and development capabilities and a reputation for bringing innovation to patients,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We believe Chugai's technology-driven drug discovery approach for innovation and development capabilities aligns seamlessly with Rani’s expertise in developing oral antibodies, peptides, and large proteins with high bioavailability. At Rani, to date, we have evaluated 19 diverse molecules preclinically and completed three Phase 1 clinical trials with the RaniPill^® capsule, showcasing its broad applicability across a wide range of biologics.”

“At Chugai, we are committed to developing innovative drug discovery technologies based on our technology-driven approach. We are honored to have the opportunity to evaluate Rani’s technology, which proposes a pioneering and innovative approach that may potentially unlock significant value across multiple programs,” said Tom Igawa, PhD, Head of Research of Chugai Pharmaceutical Co., Ltd.